Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody.

Identifying functionally critical regions of the malaria antigen AMA1 (apical membrane antigen 1) is necessary to understand the significance of the polymorphisms within this antigen for vaccine development. The crystal structure of AMA1 in complex with the Fab fragment of inhibitory monoclonal anti...

Full description

Bibliographic Details
Main Authors: Andrew M Coley, Aditi Gupta, Vince J Murphy, Tao Bai, Hanna Kim, Michael Foley, Robin F Anders, Adrian H Batchelor
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2007-09-01
Series:PLoS Pathogens
Online Access:http://europepmc.org/articles/PMC2323298?pdf=render
id doaj-72a8c7e57f1147d08a0cea15dfee8740
record_format Article
spelling doaj-72a8c7e57f1147d08a0cea15dfee87402020-11-24T22:09:33ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742007-09-01391308131910.1371/journal.ppat.0030138Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody.Andrew M ColeyAditi GuptaVince J MurphyTao BaiHanna KimMichael FoleyRobin F AndersAdrian H BatchelorIdentifying functionally critical regions of the malaria antigen AMA1 (apical membrane antigen 1) is necessary to understand the significance of the polymorphisms within this antigen for vaccine development. The crystal structure of AMA1 in complex with the Fab fragment of inhibitory monoclonal antibody 1F9 reveals that 1F9 binds to the AMA1 solvent-exposed hydrophobic trough, confirming its importance. 1F9 uses the heavy and light chain complementarity-determining regions (CDRs) to wrap around the polymorphic loops adjacent to the trough, but uses a ridge of framework residues to bind to the hydrophobic trough. The resulting 1F9-AMA1-combined buried surface of 2,470 A(2) is considerably larger than previously reported Fab-antigen interfaces. Mutations of polymorphic AMA1 residues within the 1F9 epitope disrupt 1F9 binding and dramatically reduce the binding of affinity-purified human antibodies. Moreover, 1F9 binding to AMA1 is competed by naturally acquired human antibodies, confirming that the 1F9 epitope is a frequent target of immunological attack.http://europepmc.org/articles/PMC2323298?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Andrew M Coley
Aditi Gupta
Vince J Murphy
Tao Bai
Hanna Kim
Michael Foley
Robin F Anders
Adrian H Batchelor
spellingShingle Andrew M Coley
Aditi Gupta
Vince J Murphy
Tao Bai
Hanna Kim
Michael Foley
Robin F Anders
Adrian H Batchelor
Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody.
PLoS Pathogens
author_facet Andrew M Coley
Aditi Gupta
Vince J Murphy
Tao Bai
Hanna Kim
Michael Foley
Robin F Anders
Adrian H Batchelor
author_sort Andrew M Coley
title Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody.
title_short Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody.
title_full Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody.
title_fullStr Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody.
title_full_unstemmed Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody.
title_sort structure of the malaria antigen ama1 in complex with a growth-inhibitory antibody.
publisher Public Library of Science (PLoS)
series PLoS Pathogens
issn 1553-7366
1553-7374
publishDate 2007-09-01
description Identifying functionally critical regions of the malaria antigen AMA1 (apical membrane antigen 1) is necessary to understand the significance of the polymorphisms within this antigen for vaccine development. The crystal structure of AMA1 in complex with the Fab fragment of inhibitory monoclonal antibody 1F9 reveals that 1F9 binds to the AMA1 solvent-exposed hydrophobic trough, confirming its importance. 1F9 uses the heavy and light chain complementarity-determining regions (CDRs) to wrap around the polymorphic loops adjacent to the trough, but uses a ridge of framework residues to bind to the hydrophobic trough. The resulting 1F9-AMA1-combined buried surface of 2,470 A(2) is considerably larger than previously reported Fab-antigen interfaces. Mutations of polymorphic AMA1 residues within the 1F9 epitope disrupt 1F9 binding and dramatically reduce the binding of affinity-purified human antibodies. Moreover, 1F9 binding to AMA1 is competed by naturally acquired human antibodies, confirming that the 1F9 epitope is a frequent target of immunological attack.
url http://europepmc.org/articles/PMC2323298?pdf=render
work_keys_str_mv AT andrewmcoley structureofthemalariaantigenama1incomplexwithagrowthinhibitoryantibody
AT aditigupta structureofthemalariaantigenama1incomplexwithagrowthinhibitoryantibody
AT vincejmurphy structureofthemalariaantigenama1incomplexwithagrowthinhibitoryantibody
AT taobai structureofthemalariaantigenama1incomplexwithagrowthinhibitoryantibody
AT hannakim structureofthemalariaantigenama1incomplexwithagrowthinhibitoryantibody
AT michaelfoley structureofthemalariaantigenama1incomplexwithagrowthinhibitoryantibody
AT robinfanders structureofthemalariaantigenama1incomplexwithagrowthinhibitoryantibody
AT adrianhbatchelor structureofthemalariaantigenama1incomplexwithagrowthinhibitoryantibody
_version_ 1725811306499407872